Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 17/20 | 0.75 |
| ▸ | CA1 | P00915 | 16/20 | 0.75 |
| ▸ | CA2 | P00918 | 16/20 | 0.75 |
| ▸ | CA12 | O43570 | 7/20 | 0.72 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.66 |
| ▸ | CA7 | P43166 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23169164 | 0.96 | CA9 (0.78) | CA9CA1CA2CA12CA14 | |
| SCHEMBL15828111 | 0.94 | CA9 (0.83) | CA9CA1CA2CA12CA14 | |
| SCHEMBL23169167 | 0.94 | CA1 (0.77) | CA9CA1CA2CA12CA14 | |
| SCHEMBL2234764 | 0.93 | CA9 (0.83) | CA9CA1CA2CA12CA14 | |
| SCHEMBL13097493 | 0.91 | CA9 (0.75) | CA9CA1CA2CA12CA14 | |
| SCHEMBL19788026 | 0.91 | CA9 (0.62) | CA9CA1CA2CA12CA14 | |
| SCHEMBL29699213 | 0.89 | CA9 (0.78) | CA9CA1CA2CA12CA14 | |
| SCHEMBL412012 | 0.89 | CA9 (0.78) | CA9CA1CA2CA12CA14 | |
| SCHEMBL23169163 | 0.89 | CA9 (0.70) | CA9CA1CA2CA12CA14 | |
| SCHEMBL12231957 | 0.89 | CA9 (0.72) | CA9CA1CA2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044200-B2 | Enhance immunology response; ion exchanging with chromatography support | ENDOCYTE, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20080207625-A1 | Synthesis and Purification of Pteroic Acid and Conjugates Thereof | ENDOCYTE, INC. (US) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207625-A1 | Synthesis and Purification of Pteroic Acid and Conjugates Thereof | DHFR, SLC46A1, FOLR1 | CA9 1529/4885CA1 1765/4885CA2 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.